CVS Health revealed on Wednesday that it intends to separate into two distinct publicly traded entities by the first half of 2028. The split would divide the company’s retail pharmacy operations, encompassing approximately 9,000 locations, from its Aetna insurance business and Caremark pharmacy benefit manager division.
The proposal represents a reversal from a similar consideration the company examined more than two years prior, when analysts expressed skepticism about whether the retail pharmacy segment could operate independently. The company’s financial trajectory has shifted substantially since that earlier evaluation. CVS’s pharmacy business has achieved greater consistency in profitability, while Aetna has demonstrated operational improvements despite ongoing medical cost pressures within Medicare Advantage offerings. Additionally, the company recently generated roughly $15.5 billion in operating cash flow in 2026, representing approximately a 70% increase from $9.1 billion in 2024.
CEO David Joyner attributed the timing to the company’s strengthened position. He noted that in 2024, CVS was undergoing a turnaround with insufficient flexibility and financial capacity to execute a separation. Since assuming leadership in 2024, Joyner implemented cost reductions totaling $2 billion alongside store closures, personnel changes, and initiatives to control Medicare Advantage expenses. The company has exceeded Wall Street earnings expectations for eight consecutive quarters and elevated its guidance multiple times over the preceding two years. Joyner stated the decision emerged “out of strength” rather than necessity.
The retail pharmacy segment, while remaining a relatively low-margin operation with adjusted operating margins between 4% and 5%, has benefited from competitive consolidation within the industry. Walgreens, Rite Aid, and other pharmacy chains have substantially reduced their footprints, enabling CVS to capture market share. The company also implemented its CostVantage program to replace traditional reimbursement processes with a more transparent, cost-based model, potentially improving profit stability.
Investor reaction proved mixed. While CVS stock declined approximately 12% following the announcement, analysts noted that the lower valuation assigned to the retail pharmacy unit has historically suppressed the company’s overall value and obscured stronger earnings performance from insurance and pharmacy benefit management operations. The separation also occurs amid intensifying regulatory scrutiny of pharmacy benefit manager practices at the state level, though company leadership stated regulatory pressures did not drive the decision.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI